Evaluation and Management of Miosis
Miosis evaluation should focus on identifying the underlying cause through targeted history (medication exposure, toxins, neurologic symptoms) and examination (pupillary reactivity, associated neurologic deficits), with management directed at the specific etiology rather than the miosis itself.
Clinical Context Matters
The approach to miosis depends entirely on the clinical scenario in which it presents:
Intraoperative Miosis (During Eye Surgery)
For intraoperative miosis during cataract or vitreoretinal surgery, prevention is more effective than treatment:
- Preoperative NSAID prophylaxis: Topical indomethacin 0.1% three times daily for 3 days before surgery, plus three additional doses at 30-minute intervals in the 2 hours before surgery reduces pupillary narrowing 1
- Adding intramuscular diclofenac 1 hour preoperatively provides marginal additional benefit (6.7% vs 8.2% pronounced miosis) 1
- Timing is critical: Keep the interval between femtosecond laser stage and phacoemulsification under 15 minutes to minimize miosis 1
- Risk factors include surgery duration >90 minutes, preoperative afferent pupillary defect, and recent previous surgery 2
If miosis occurs intraoperatively, viscomydriasis using viscoadaptive viscoelastic (sodium hyaluronate 2.3%) effectively restores and maintains pupillary dilation 3. This is a simple mechanical technique that works reliably when pharmacologic dilation fails.
Miosis as a Toxicologic Sign
Bilateral reactive miosis in an altered or comatose patient should prompt immediate evaluation for:
- Opioid overdose (most common)
- Cholinergic toxicity (organophosphates, carbamates)
- Pontine lesions (though pupils are typically pinpoint and poorly reactive)
A critical caveat: Severe insulin intoxication can cause prolonged bilateral reactive miosis lasting up to 4 days, likely from relative pontine hypoperfusion during hypoglycemia 4. This is easily missed if you're not thinking about it—check blood glucose immediately in any patient with unexplained miosis and altered mental status.
Iatrogenic Miosis (Pilocarpine for Presbyopia)
The FDA-approved use of 1.25% pilocarpine for presbyopia intentionally induces miosis to increase depth of focus. This does not adversely affect visual acuity in presbyopic patients under varying contrast and luminance conditions 5, making it a viable option for those who refuse corrective lenses.
However, miosis does reduce mean sensitivity on automated perimetry by 1.6-1.8 dB when pupil size decreases below 2mm 6. This applies equally to glaucoma patients and normal subjects, so visual field testing should ideally be performed with pupils >3mm for accurate comparison over time.
Key Evaluation Steps
- Determine pupillary reactivity: Reactive miosis suggests intact neurologic pathways (toxins, drugs); non-reactive suggests structural damage
- Assess for associated symptoms: Altered mental status, respiratory depression, excessive secretions, neurologic deficits
- Medication/exposure history: Opioids, pilocarpine, organophosphates, topical miotics
- Blood glucose: Rule out severe hypoglycemia in unexplained cases 4
- Toxicology screen: If clinical suspicion for overdose
- Neuroimaging: Only if focal neurologic signs or concern for structural lesion
Management Algorithm
- Opioid-induced: Naloxone titrated to effect
- Cholinergic toxicity: Atropine, pralidoxime for organophosphates
- Hypoglycemia-related: Continuous IV glucose until resolution 4
- Intraoperative: Viscomydriasis with viscoadaptive viscoelastic 3
- Iatrogenic (pilocarpine): Reassurance if intentional; discontinue if unintended
The miosis itself rarely requires direct treatment—address the underlying cause and pupillary size will normalize as the condition resolves.